Synchrony progress several exciting projects
Synchrony launch in the UK a unique presentation of Labetalol 5mg/ml offering convenience and efficiencies
Synchrony launch in the UK the only licensed “ready to use” Magnesium Sulfate 20% w/v
New Product Marketing Authorisations
Synchrony received a UK marketing authorisation for Magnesium Sulfate 10%w/v and 20%w/v. A number of other Synchrony product developments are advancing through the regulatory approval process.
Wave 11 tender award
Synchrony are pleased to announce the award to supply three hospital products in the latest NHS tender. This further strengthens our position as a partner of choice in the UK market.
Synchrony met with several development and commercial partners. An agreement to develop two further speciality products signed. To add to our commercial network a further two out-licensing deals were concluded.
CPhI China, 20th – 22nd June 2017
Synchrony Pharma will attend CPhI China to meet with existing and potential new partners to further our development pipeline. Please contact us to arrange any meetings to discuss co-developments, contract development and licensing deals.
Wave 10c tender award
We are pleased to announce that Synchrony has been awarded significant contracts across several products in the latest NHS tender. This continues our strong performance in NHS tenders and further strengthens our UK business.
Niche generic portfolio advances
Synchrony has received Day 100 questions from the MHRA on two MA applications for our Niche Generic portfolio. A comprehensive response is being prepared to move these products towards commercialisation.
Synchrony has been awarded a contract by NHS Wales, further expanding the number of hospitals we support in the UK.
New injectable product development deal
Synchrony has signed an agreement for the development of two generic injectable products. These products have great commercial potential in both the UK and globally. UK MHRA MA applications are planned for the second half of 2017.
CPhI Barcelona, 4th – 6th October 2016
Synchrony will be attending CPhI in Barcelona from 4th to 6th October 2016. Please contact us to arrange any meetings.
Submission of niche generic to MHRA
Synchrony has submitted its application for a Marketing Authorisation of a niche injectable formulation further broadening its portfolio and renewing its commitment to novel and niche product developments. Further news to appear here.
Pemetrexed 500mg EU DCP approved
Synchrony Pharma’s development of Pemetrexed has gained EU approval in several markets via a DCP procedure. This is further validation of Synchrony Pharma’s robust approach to product development. Commercialisation planning for early entry markets in underway.
Synchrony will be attending euroPLX 60 in Barcelona from 7th to 8th March 2016.
Two in licensing deals announced
Following CPhI Madrid in October Synchrony has finalised two further in-license deals for injectable products for the UK. Further in-license and development projects are in the pipeline.
Synchrony will be attending CPhI in Madrid from 13th to 15th October 2015.
First to market on Bortezomib
Following the approval of Synchrony’s Bortezomib dossier earlier in the year our partner network has successfully launched as first to market Czech Republic and Slovakia.
Synchrony will be attending euroPLX 58 in Munich from 1st to 2nd June 2015.
Synchrony awarded contract in latest NHS tender
The Commercial Medicines Unit have awarded Synchrony supply contracts in the latest generic tender wave. The contract will run until 2017 and continues Synchrony’s successful history in UK tenders.
Bortezomib 3.5mg EU DCP approved
Synchrony Pharma’s development of Bortezomib has gained EU approval in several markets via a DCP procedure. The smooth management of the procedure and this positive outcome now position Synchrony’s partners to be amongst the first to market in certain countries.